Table 1.
The clinic-pathologic characteristics of luminal B HER2-negative breast cancer
| ER and PR positive N = 160 (%) |
ER or PR negative N = 24 (%) |
p value | |
|---|---|---|---|
| Age (years) median | 48.5 | 55.5 | 0.0336 |
| = or <45 | 59 (36.9) | 3 (12.5) | |
| >45 | 101 (62.1) | 21 (87.5) | |
| TNM stage (AJCC 8th) | 0.1061 | ||
| I | 50 (31.2) | 5 (20.8) | |
| II | 81 (50.6) | 11 (45.8) | |
| III | 27 (16.9) | 6 (25.0) | |
| IV | 2 (1.3) | 2 (8.3) | |
| Breast operation | 0.8761 | ||
| BCS | 113 (70.6) | 16 (66.7) | |
| Mastectomy | 47 (29.4) | 8 (33.3) | |
| Axillary node operation | 0.2088 | ||
| SLNB | 63 (39.4) | 7 (29.2) | |
| ALND | 96 (60.0) | 16 (66.7) | |
| omit | 1 (0.6) | 1 (4.2) | |
| Histologic type | 0.1587 | ||
| Invasive ductal carcinoma | 142 (88.8) | 22 (91.7) | |
| Invasive Lobular carcinoma | 5 (3.1) | 2 (8.3) | |
| Mucinous carcinoma | 6 (3.8) | 0 (0) | |
| Papillary carcinoma | 6 (3.8) | 0 (0) | |
| Micropapillary carcinoma | 3 (1.9) | 0 (0) | |
| Apocrine carcinoma | 1 (0.3) | 0 (0) | |
| Histologic grade | 0.4421 | ||
| II | 31 (19.4) | 8 (33.3) | |
| III | 101 (63.1) | 16 (66.7) | |
| Not available | 28 (17.5) | 0 (0) | |
| Nuclear grade | 0.9403 | ||
| I | 82 (51.2) | 14 (58.3) | |
| II | 45 (28.1) | 9 (37.5) | |
| III | 5 (3.1) | 1 (4.2) | |
| Not available | 28 (17.5) | 0 (0) | |
| Number of tumor | 0.6269 | ||
| Single | 137 (85.6) | 22 (91.7) | |
| Multiple | 23 (14.4) | 2 (8.3) | |
| Bcl-2 expression | 0.0006 | ||
| = or <10 % | 17 (10.9) | 11 (39.3) | |
| >10 % | 139 (89.1) | 17 (60.7) | |
| Ki 67 | 0.0167 | ||
| = or <50 % | 136 (85.0) | 15 (62.5) | |
| >50 % | 24 (15.0) | 9 (37.5) | |
| Adjuvant therapy | |||
| Chemotherapy | |||
| Yes | 133 (83.1) | 22 (91.7) | 0.1321 |
| Anthracycline/taxane based | 72 (45.0) | 17 (70.8) | |
| CMF or CNF based | 50 (36.9) | 5 (20.7) | |
| No | 27 (16.9) | 2 (8.3) | |
| Hormonal therapy | |||
| Yes | 148 (92.5) | 22 (91.7) | 0.0579 |
| SERM | 100 (62.5) | 9 (37.5) | |
| AI | 49 (30.6) | 13 (54.2) | |
| No | 11 (6.9) | 2 (8.3) | |
| Radiation therapy | |||
| Yes | 110 (68.7) | 17 (70.8) | 0.9752 |
| No | 50 (31.2) | 7 (29.2) | |
TNM tumor size/node/metastasis, AJCC American Joint Committee on Cancer, BCS breast conserving surgery, SLNB sentinel lymph node biopsy, ALND axillary lymph node dissection, SERM selective estrogen receptor modulator, AI aromatase inhibitor, CMF cyclophosphamide/methotrexate/5-fluorouracil, CNF cyclophosphamide/vinorelbine/5-fluorouracil